SANA at a glance
Sana Biotechnology, Inc. (SANA, SEC CIK 1770121) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Sana Biotechnology, Inc. (SANA) shares worth $179.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $179.7M · −3 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved for sale
- Net income $20.4M vs net loss $42.2M YoY, driven by $63.4M contingent consideration gain
- R&D expense $33.9M, up $3.8M YoY, driven by SC451 and SG293 manufacturing costs
- Cash, equivalents and securities $121.7M; nine-month operating cash use $108.9M
- Outlook: additional capital needed within 12 months, substantial going-concern doubt, SC451 and SG293 prioritized
Risk Factors
- New H-1B visa risk, triggered by a new one-time $100,000 fee for new petitions and proposed program reforms
- Portfolio prioritization risk, November 2025 suspension of SC291 and SC262 development reduced pipeline breadth and increased reliance on SC451 and SG293
- Regulatory risk, FDA boxed-warning scrutiny for CAR T malignancies could impose additional requirements on in vivo CAR T programs
- Operational risk, limited NHP model availability has delayed preclinical studies and increased costs
- Financial risk, substantial losses and going-concern uncertainty create dependence on additional capital for operations
AI summary of the SANA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Detailed results and management commentary contained in Exhibit 99.1, the accompanying press release
Item EX-99.1: Item EX-99.1
- Cash $121.7M at September 30, 2026, with runway into mid-2027, but nine-month non-GAAP operating cash burn reached $103.4M
- SC451 IND and Phase 1/2 trial targeted as early as 2026, creating a near-term clinical catalyst in type 1 diabetes
Item EX-99.1: Item EX-99.1
- SC451 IND filing and Phase 1/2 initiation targeted for 2026, creating near-term clinical catalysts in type 1 diabetes
- UP421 demonstrated hypoimmune islet-cell survival and function through 14 months without immunosuppression
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation released September 8, 2026 for investor-conference discussions
- Exhibit 99.1 contains the presentation, potentially detailing updated strategy, pipeline, or clinical priorities
Item EX-99.1: Item EX-99.1
- Q2 net loss improved to $63.6M, or $0.22 per share, from $93.8M, benefiting from no 2025 impairment charge
- Cash, equivalents, and marketable securities reached $160.5M, supported by $93.3M financing proceeds and providing runway into mid-2027
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Exhibit 99.1 contains Sana Biotechnology’s detailed earnings release for investor review
AI summaries of SANA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SANA
Don't miss the next SANA filing
- Alerts as it files. A push when SANA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SANA, by share count.
- Ask anything. An AI agent that reads every SANA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bishop Hans Edgar | A | Oct 5, 2026 | 8,680 | - |
| PATEL DHAVALKUMAR DHIRAJLAL | F | Aug 27, 2026 | 41,158 | $4.11 |
| PATEL DHAVALKUMAR DHIRAJLAL | M | Aug 26, 2026 | 125,000 | - |
| PATEL DHAVALKUMAR DHIRAJLAL | M | Aug 26, 2026 | 125,000 | - |
| Bishop Hans Edgar | A | Jul 6, 2026 | 6,297 | - |
| Rosiello Robert L. | A | Jun 4, 2026 | 90,000 | - |
| REICIN ALISE | A | Jun 4, 2026 | 90,000 | - |
| Yang Patrick Y | A | Jun 4, 2026 | 90,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$293.1M | -$272.7M | -$250.3M |
| Net Income | -$283.3M | -$266.8M | -$244.2M |
| Balance Sheet | |||
| Total Assets | $565.3M | $501.0M | $416.9M |
| Equity | $287.5M | $250.5M | $160.9M |
| ROE | -98.5% | -106.5% | -151.8% |
| Per Share | |||
| EPS | - | $-1.16 | $-0.96 |
| Cash Flow | |||
| Operating CF | -$253.6M | -$223.2M | -$143.8M |
| CapEx | $20.0M | $33.4M | $938K |
Source: XBRL data in Sana Biotechnology, Inc. (SANA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SANA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $179.7M |
| Q2 2026 | 32 | $348.7M |
| Q1 2026 | 30 | $275.7M |
| Q4 2025 | 27 | $368.8M |
| Q3 2025 | 26 | $332.0M |
| Q2 2025 | 28 | $210.9M |
| Q1 2025 | 24 | $102.3M |
| Q4 2024 | 20 | $98.3M |
- Morgan Stanley+1.88M (+165%)
- Citadel Advisors LLC+1.04M (+642%)
- Goldman Sachs Group+312.6K (+13%)
- Vanguard Capital Management LLC+235.8K (+3%)
- Renaissance Technologies LLC+190.4K (+15%)
- State Street Corp−1.62M (-14%)
- Bank of America Corp−1.12M (-19%)
- AQR Capital Management−457.1K (-47%)
- Two Sigma Investments−349.1K (-55%)
- BlackRock−290.9K (-2%)
- Franklin Resources+261.1K
- FMR LLC (Fidelity)−37.43M
- Ameriprise Financial−120.3K
- D.E. Shaw & Co−40.1K
- Fifth Third Bancorp−5.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 216 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SANA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 27, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| SC 13G | May 21, 2026 | - | - | |
| 8-K | May 15, 2026 | - | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 24, 2026 | - | Analysis | - |
| 8-K | Apr 13, 2026 | - | Analysis | - |
| 4 | Apr 8, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
SANA SEC filings: frequently asked questions
Which institutions hold SANA stock?
As of September 30, 2026, the largest Sana Biotechnology, Inc. (SANA) holders among the 13F filers tracked by SignalX were BlackRock ($47.8 million), State Street Corp ($27.9 million), Vanguard Capital Management LLC ($25.1 million), Bank of America Corp ($13.5 million), Marex Group plc ($11.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did SANA report in its latest 8-K?
Sana Biotechnology, Inc. (SANA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest SANA SEC filings?
Sana Biotechnology, Inc. (SANA) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 6, 2026.
What is SANA's SEC CIK number?
Sana Biotechnology, Inc. (SANA)'s SEC Central Index Key (CIK) is 1770121. EDGAR lists every SANA filing under that number.
Ask anything about SANA
The research agent reads SANA's filings, financials, insider trades and 13F holders, then answers with sources.